Evidence map›Paper›PMID 39000366›Full record

ArticleInternational journal of molecular sciences2024

Self-Assembling Nanoparticle Hemagglutinin Influenza Vaccines Induce High Antibody Response.

Hongying Ren, Bin Zhang, Xinwei Zhang, Tiantian Wang, Xvchen Hou, Xianyong Lan, Chuanying Pan, Jun Wu, Bo Liu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongying RenDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Bin ZhangDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Xinwei ZhangKey Laboratory of Animal Genetics, Breeding and Reproduction of Shaanxi Province, College of Animal Science and Technology, Northwest A&F University, Yangling, Xianyang 712100, China.
Tiantian WangDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Xvchen HouDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Xianyong LanKey Laboratory of Animal Genetics, Breeding and Reproduction of Shaanxi Province, College of Animal Science and Technology, Northwest A&F University, Yangling, Xianyang 712100, China.
Chuanying PanKey Laboratory of Animal Genetics, Breeding and Reproduction of Shaanxi Province, College of Animal Science and Technology, Northwest A&F University, Yangling, Xianyang 712100, China.
Jun WuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
Bo LiuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.ORCID 0000-0001-6655-1866

Funding

National Key R&D Program of China 2022YFC2104801
6 · The paper itself

Abstract

As a highly pathogenic avian virus, H5 influenza poses a serious threat to livestock, the poultry industry, and public health security. Hemagglutinin (HA) is both the dominant epitope and the main target of influenza-neutralizing antibodies. Here, we designed a nanoparticle hemagglutinin influenza vaccine to improve the immunogenicity of the influenza vaccine. In this study, HA5 subtype influenza virus was used as the candidate antigen and was combined with the artificially designed double-branch scaffold protein I53_dn5 A and B. A structurally correct and bioactive trimer HA5-I53_dn5B/Y98F was obtained through secretion and purification using an insect baculovirus expression system; I53_dn5A was obtained by purification using a prokaryotic expression system. HA5-I53_dn5B/Y98F and I53_dn5A self-assembled into spherical nanoparticles (HA5-I53_dn5) in vitro with a diameter of about 45 nm. Immunization and serum test results showed that both HA5-I53_dn5B/Y98F and HA5-I53_dn5 could induce HA5-specific antibodies; however, the immunogenicity of HA5-I53_dn5 was better than that of HA5-I53_dn5B/Y98F. Groups treated with HA5-I53_dn5B and HA5-I53_dn5 nanoparticles produced IgG antibody titers that were not statistically different from those of the nanoparticle-containing adjuvant group. This production of trimerized HA5-I53_dn5B and HA5-I53_dn5 nanoparticles using baculovirus expression provides a reference for the development of novel, safe, and efficient influenza vaccines.

Indexed as

Antibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNanoparticlesAnimalsAntibodies, NeutralizingAntibody FormationFemaleHumansMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccinesbaculovirus expression systemH5 subtype influenza virushemagglutininnanoparticle vaccine

Identifiers

PMID39000366
PMCPMC11241447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.